Phase I, two-way, crossover study to demonstrate bioequivalence and to compare safety and tolerability of single-dose XM17 vs Gonal-f® in healthy women after follicle-stimulating hormone downregulation
Crossref DOI link:
Published Online: 2015-12-01
Published Print: 2015-12
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Funding for this research was provided by:
BioGeneriX AG, now incorporated into Merckle GmbH, a member of the Teva group
Teva Branded Pharmaceutical Products R&D, Inc.